REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Emphasys Medical Inc., today announced that one-year data from the VENT clinical trial of the company's Zephyr(R) Endobronchial Valve (EBV) will be presented at the International Conference of the American Thoracic Society (ATS) occurring May 16 to 21 in Toronto, Canada.
Sunday, May 18, 9:30-11:00 a.m. (ET), Metro Toronto Convention Centre, Room 801A
In the symposium, "Innovations in Emphysema Treatment: Lung Volume
Reduction and Lung Volume Reduction Surgery," Zephyr related presentations
-- Frank Sciurba, M.D., University of Pittsburgh Medical Center, the
principal investigator of VENT, will present on the Durability of
Endobronchial Valve Effect on Lung Function at 6 and 12 Months.
-- Jonathan Goldin, M.D., Ph.D., University of California at Los Angeles,
the principal investigator of the VENT radiology core lab, will
present on Fissure Integrity As a Marker of Collateral Ventilation
Across Lung Lobes.
-- Jim Egan, M.D., Mater Misericordiae Hospital, Dublin, Ireland, will
present on the Treatment of Advanced Emphysema by Endoscopic Volume
-- John Travaline, M.D., Temple University, will present on the Efficacy
of Endobronchial Valves in the Treatment of Persistent Air Leaks.
Monday, May 19, 8:30 a.m., Metro Toronto Convention Centre, Room 715A
-- Charlie Strange, M.D., Medical University of South Carolina will
present on the relation of FEV1/FVC and Fissure Integrity in the VENT
Monday, May 19, 3:10 p.m., Metro Toronto Convention Centre, Hall G
-- Frank Sciurba, M.D., will present on Bronchoscopic Methods for
Palliation of Emphysema.
About the Zephyr Endobronchial Valve
The Zephyr EBV is a novel, minimally-invasive device intended to treat
emphysema. The Zephyr EBV is designed to i
|SOURCE Emphasys Medical Inc.|
Copyright©2008 PR Newswire.
All rights reserved